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Of 52 patients with recurrent tuberculosis in Shanghai,
People’s Republic of China, 32 (61.5%) had isolates in
which genotype patterns of Mycobacterium tuberculosis
differed between first and second episodes. This result indi-
cates that exogenous reinfection is common in an area with
a high incidence of tuberculosis.
E
lucidating the role of reinfection in tuberculosis (TB)
recurrence is important in the People’s Republic of
China because this country has the second highest inci-
dence of TB in the world, an estimated rate in 2004 of 101
cases/100,000 persons/year (1).After effective short-
course therapy for active TB, some patients experience
another, recurrent TB episode. The recurrent episode may
be due to endogenous reactivation or exogenous reinfec-
tion. The role of exogenous reinfection has been debated
for decades (2,3). Understanding the cause for recurrence
helps clinicians evaluate the effectiveness of therapeutic
regimens and TB prevention and control programs to
assess strategies and interventions.
DNA fingerprinting techniques provide excellent tools
to address whether recurrent TB is caused by endogenous
reactivation or exogenous reinfection. Different
Mycobacterium tuberculosis strains can be differentiated
by genotyping methods that use information about genetic
markers and their distribution in the genome (4). Among
persons with recurrent TB, if the isolates from 2 TB
episodes have the same genotype, the episode is defined as
an endogenous relapse; otherwise, it is defined as exoge-
nous reinfection. Previously, researchers have tried to
assess the relative importance of endogenous relapse ver-
sus exogenous reinfection, with varied results (2,5–10).
Our study helps elucidate the role of reinfection in TB
recurrence in China.
The Study
Shanghai is 1 area in China with high TB treatment suc-
cess rates. Persons with TB symptoms (mainly cough for
at least 2 weeks, chest pain, weight loss, and fever) can go
to any hospital or community health center in Shanghai.
They are first screened by chest radiograph. All patients
with suspected TB are referred to a TB hospital, where
sputum is examined by smear and culture. TB is bacterio-
logically confirmed if >1 sputum smear examination result
was positive for acid-fast bacilli or if the culture was pos-
itive. The TB hospital sends all mycobacteria-positive cul-
tures to the TB reference laboratory at the Shanghai
Municipal Centers for Disease Control and Prevention
(Shanghai CDC), which participated in the World Health
Organization/International Union against Tuberculosis and
Lung Disease global drug resistance surveillance project,
for species identification and drug susceptibility testing.
TB patients are treated in the TB hospital during the inten-
sive phase. On the basis of the sputum smear and culture
examination 1 or 2 months after TB therapy is initiated, the
patient is discharged from the hospital and finishes treat-
ment as an outpatient. The community health center physi-
cian trains family members to supervise and observe the
TB patient’s remaining doses and treatment. Completion
of anti-TB therapy is based on the examination of sputum
smear, culture, and chest radiographic results. Shanghai
CDC collects and manages patient information, such as
social and demographic characteristics, clinical data, TB
treatment regimens, and the result of drug susceptibility
testing and species identification. 
From January 1999 through September 2004, Shanghai
CDC collected 6,442 clinical isolates from a total of 6,960
persons with bacteriologically confirmed (by smear or cul-
ture) TB. Of these case-patients, 5,688 were cured, and
202 (164 male and 38 female) had a recurrence, defined by
the following criteria: 1) their TB episode was confirmed
by culture; and 2) they experienced 2 successive TB
episodes, with cure as the outcome of the first episode.
Cure was defined as the completion of a standard course of
combination therapy and successive negative sputum cul-
tures during treatment. At the same time, chest radiography
showed resolution of the focus of infection. On the basis of
the selection criteria, 54 patients with recurrent TB were
included in the study (Figure 1).
The mycobacterial interspersed repetitive unit (MIRU)
typing method (11) was used to genotype strains from
these patients. This method is relatively easier to perform
and less technically demanding than IS6110 restriction
fragment length polymorphism (IS6110-RFLP), which
was used in many previous molecular epidemiologic stud-
ies of TB (12). We followed the protocol described by
Kwara et al. (13) with modifications. PCR products were
analyzed by 2.5% (w/v) agarose gel electrophoresis
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Shanghai, People’s Republic of China(Figure 2A). Genotyping was performed for 2 isolates. We
analyzed the data for the remaining 52 patients and found
MIRU patterns for both episodes to be the same for 20
patients and different for 32. Of these 32 patients, 13 had
1 MIRU locus change between the 2 isolates, 10 had a
change in 2 loci, and 9 had >3 loci changes in their isolates
(online Appendix Table, available from http://www.cdc.
gov/ncidod/EID/vol12no11/05-1207_appT.htm). These
results indicate that 32 (61.5%) of 52 (95% confidence
interval 47.0%–74.4%) of the recurrent cases were due to
reinfection. To further validate the MIRU genotype result,
the IS6110  RFLP genotyping method was performed;
results showed that the isolates with 1 or 2 MIRU locus
changes had very different RFLP patterns (a difference in
>4 bands in the IS6110-RFLP, Figure 2B).
We further used patient age group and intervals
between the 2 episodes to classify recurrent TB. We found
that the percentage of TB patients with an exogenous rein-
fection decreased with age from 100% (TB patients <30
years of age) to 66.7% (TB patients 30–60 years) and
53.3% (TB patients >60 years). We also found that the fre-
quency of exogenous reinfection increased with the
amount of time that elapsed between the end of TB treat-
ment for the first episode of TB and the date that the sec-
ond episode was diagnosed. Exogenous reinfection
accounted for 7 (46.7%) of the 15 recurrent episodes that
occurred within 6 months after treatment for the first
episode; the percentage of recurrent cases due to exoge-
nous reinfection increased to 73.9% (17/23) among TB
patients whose second episode occurred >1 year after
treatment for the first episode.
Conclusions
We analyzed genotypes of 104 isolates from 52 patients
who experienced 2 TB episodes from 1999 through 2004.
Thirty-two of 52 patients had different MIRU genotype
patterns in clinical isolates from their 2 episodes, which
indicates that exogenous reinfection accounted for 61.5%
of the recurrent cases in Shanghai during the study period.
The high proportion of exogenous reinfection in recurrent
TB patients indicates that high levels of transmission of M.
tuberculosis are an important cause of TB in Shanghai,
China.
Although several reports have indicated that exogenous
reinfection may occur after successful treatment, the pro-
portion of TB cases that are actually caused by exogenous
reinfection may vary dramatically for several reasons, such
as the patients’ HIV infection status, different facilities,
and healthcare providers’ various definitions (some used
different numbers of days elapsed between the first and
second episode to define a recurrent case of TB), and par-
ticularly the small sample size (2). Several studies have
reported that HIV may be a risk factor for exogenous rein-
fection (2,14,15). Unfortunately, we do not have data on
each patient’s HIV infection status, and we cannot totally
exclude the effect of HIV infection. However, considering
the low incidence of HIV infection among residents of
Shanghai (≈0.6 cases/100,000 persons/year), we consider
it unlikely that HIV is a major factor in our findings. The
criteria used to define recurrent TB cases differ; various
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Figure 1. Selection of patients in the study, Shanghai, People’s
Republic of China, 1999–2004. TB, tuberculosis. The total number
of patients from 1999 through 2004 was 6,960; among these
patients, 5,688 were cured.
Figure 2. Genotyping analysis of clinical isolates from patients with
recurrent tuberculosis. Numbers represented the patients' codes.
A) Gel electrophoresis analysis of the PCR products of the
mycobacterial interspersed repetitive unit (MIRU) locus 10. bp,
base pair; M: DNA marker; Rv, H37Rv positive control; ck, nega-
tive control. B) IS6110 restriction fragment length polymorphism
analysis of some patients with different MIRU patterns.studies defined the interval between the end of TB treat-
ment and a new episode (recurrent TB) as 3–12 months
(5,7,8). Our study did not define the interval and deter-
mined that 61.5% of the recurrent TB cases were due to
exogenous reinfection. If we chose a 6-month interval to
define a recurrent TB case, then we would find an even
higher percentage of recurrent TB cases were due to
exogenous reinfection (67.6%, 25/37).
Previous studies and our study demonstrate that TB
patients can be reinfected with a new strain of M. tubercu-
losis after treatment, which indicates that the immunity
evoked by the primary infection does not protect the
patient against a later infection. A recent study from South
Africa demonstrated that the rate of TB reinfection after
successful treatment is even higher than the rate of new TB
infection (5). Such results suggest major challenges for the
development of a new vaccine that will be effective against
M. tuberculosis.
In summary, our study showed that 61.5% of recurrent
TB cases in Shanghai from 1999 through 2004 were due to
exogenous reinfection and confirmed that reinfection may
be common in areas with a relatively high incidence of TB.
This finding provides important implications for TB con-
trol. To prevent recurrent TB, more attention should be
paid to the interruption of TB transmission.
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